nuclear hormone receptor


Also found in: Encyclopedia.

nuclear hormone receptor

member of large family of intracellular molecules that act as ligand-activated transcription factors; all steroid and thyroid hormones and retinoic acid exert their effects through nuclear receptors. Member molecules that have no known ligand have been called orphan nuclear receptor.

DAX1

A gene (DSS-AHC critical region on the X chromosome, gene 1—formally known, per HUGO nomenclature, as NR0B1) located on chromosome Xp21.3 that encodes a protein containing a DNA-binding domain, which acts as a dominant-negative regulator of transcription mediated by the retinoic acid receptor. DAX1 also acts as an anti-testis gene by antagonising SRY.

Molecular pathology
DAX1 mutations cause both X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism.
References in periodicals archive ?
5] M), we judged the PBDEs and their metabolites to be positive for agonistic or antagonistic activity against that nuclear hormone receptor.
Bile acids serve as metabolic integrators, activating major signaling pathways regulated by nuclear hormone receptors including the farnesoid X receptor (FXR) and G protein-coupled receptors (GPCRs) such as TGR5.
Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen's Nuclear Hormone Receptor proteins and Lanthascreen(R) assay technology with PamGene's portfolio of microarray-based Nuclear Hormone Receptor screening tools; specifically its PamChip(R) applications and PamStation(R) instrumentation.
New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator.
Glitazones appear to act primarily through the activation of nuclear hormone receptor, PPARgamma.
today announced that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to develop and commercialize novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.
We are excited to have the opportunity to build on Karo Bio's discoveries and expertise in the nuclear hormone receptor field and to develop this important new class of drug.
PPAR gamma is the third nuclear hormone receptor (NHR) available from ActiveSight for rapid co-crystal structure determination.
These new Portfolio targets expand a collection which includes the oncology targets Hsp90 and Aurora-A kinase; nuclear hormone receptor targets PPAR-delta and FXR, implicated in metabolic disorders; PDE-4 for asthma and inflammation; the hypertension target Renin; the type-II diabetes target FBPase; and the anti-infective target bacterial DNA gyrase.
today announced that it signed a license agreement with Wyeth Pharmaceuticals, a division of Wyeth related to compounds targeting the farnesoid X receptor (FXR), a nuclear hormone receptor implicated in a variety of metabolic and liver disorders.
The Portfolio includes the oncology targets Hsp90 and Aurora-A kinase; nuclear hormone receptor targets PPAR-delta and FXR, implicated in obesity; PDE-4 for asthma and inflammation; the hypertension target renin; the type-II diabetes target FBPase; and the anti-infective target bacterial gyrase.

Full browser ?